Table 4.
Sexual activity, sexual dysfunction and bowel symptoms in adults with mitochondrial disease and controls
| Patient group | Control group | Sexually active P value | Sexual dysfunction P value | Bowel symptoms P value | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Sexually active n/total n (%) | Sexual dysfunction n/total n (%) | Bowel symptoms n/total n (%) | Sexually active n/total n (%) | Sexual dysfunction n/total n (%) | Bowel symptoms n/total n (%) | |||||
| All | 22/51 (43.1) | 24/51 (47.1) | 28/55 (50.9) | All | 11/19 (57.9) | 5/19 (26.3) | 3/18 (16.7) | 0.271 | 0.100 | 0.011* |
| Females | 13/32 (40.6) | 17/32 (53.1) | 20/38 (52.6) | Females | 7/9 (77.8) | 1/9 (11.1) | 3/8 (37.5) | 0.049* | 0.026* | 0.437 |
| Males | 12/19 (63.2) | 6/19 (31.6) | 8/17 (47.1) | Males | 6/10 (60.0) | 4/10 (40.0) | 0/10 (0.0) | 0.868 | 0.650 | 0.010** |
| m.3243A>G | 9/21 (42.9) | 14/21 (66.7) | 15/24 (62.5) | All | 11/19 (57.9) | 5/19 (26.3) | 3/18 (16.7) | 0.342 | 0.011* | 0.003** |
n, number. Sexual activity within the last week and sexual dysfunction as indicated by the Arizona Sexual Experiences Scale. Bowel symptoms as indicated by a Neurogenic Bowel Dysfunction score >0. *P < 0.05; **P < 0.01, at four decimal places.